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The management of localised and advanced gastrointestinal stromal tumours (GISTs) in terms of histological diagnosis, surgery,
imaging, medical treatment and molecular biology has rapidly changed since introduction of imatinib mesylate for molecularly targeted
therapy in 2000. In this minireview, we briefly summarise and discuss the current data relevant to the increasing role of molecular
characterisation of GISTs in the diagnosis, risk assessment and effective targeted therapy.
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Gastrointestinal stromal tumours (GISTs), the most common
mesenchymal tumours of the gastrointestinal tract, hypothetically
evolve from a progenitor related to the interstitial cells of Cajal.
Population-based studies reported GIST annual incidence rates
ranging from 6.5 to 14.5 per million (Joensuu, 2006). The most
common sites of origin for GIST are stomach (39–70%) and small
intestine (31–45%), but GISTs may arise anywhere along the
gastrointestinal tract or within the abdomen as extragastrointest-
inal tumours (Demetri et al, 2007). Frequent clinical symptoms
include bloating, gastrointestinal tract bleeding, fatigue and
anaemia. Gastrointestinal stromal tumours are highly resistant to
traditional chemotherapeutic agents. The usefulness of radio-
therapy is also very limited in the therapeutic setting mostly due to
toxicity to the surrounding structures (Joensuu et al, 2002).
Surgery has been the basis of treatment for GISTs. The 5-year
survival rate is only 54% after complete resection of a localised
primary GIST (Dematteo et al, 2002). The median survival for
patients with high risk and overtly malignant tumours is o2 years
and o4 years, respectively. Independent prognostic factors that
predict the tumour-free survival are tumour size and proliferative
index (Nilssen et al, 2005). The common metastatic sites for GIST
include the liver and omentum. Due to recognition of the disease
as a separate entity, the diagnosis of GIST has dramatically
enhanced since 1998, and survival has greatly improved since
introduction of imatinib mesylate in 2000.
PATHOGENESIS, DIFFERENTIAL DIAGNOSIS AND
RISK ASSESSMENT
Identification of KIT-activating mutations as a key factor in the
pathogenesis of GIST has substantially altered the diagnosis and
treatment of GIST (Hirota et al, 1998; Corless et al, 2004; Miettinen
and Lasota, 2006). Oncogenic KIT mutations are detectable in
75–85% of all GISTs, even in small, incidentally discovered lesions.
These mutations most frequently involve the intracellular juxta-
membrane domain of the receptor encoded by exon 11 (57–70%),
followed by the extracellular domain encoded by exon 9 (5–18%).
The KIT exon 11 mutations are quite heterogeneous, encompass-
ing mainly in-frame deletions of variable sizes, basic amino acid
substitutions, or more complex deletions–insertions. The KIT
exon 9 mutations represent mainly in-frame tandem duplication,
AY502-503dup. KIT mutations in the split kinase domains I and II
(encoded by exon 13 and exon 17) appear to be rather uncommon,
accounting for 0.6–1.4% of all mutations. Alternatively, a subset
of GISTs (5–10%) carries constitutively activating mutations in
the gene encoding platelet-derived growth factor receptor
a (PDGFRA), a receptor tyrosine kinase homologous to KIT
(Heinrich et al, 2003b). The mutations reported within PDGFRA
involve exon 12, 14 and 18, being homologous to KIT exon 11, 13
and 17, respectively. In 490% of cases, PDGFRA mutations target
codons 842–849 (exon 18), with the D842V substitution being
most common. Gastrointestinal stromal tumours that harbour
different KIT or PDGFRA mutations have different molecular
signatures at the level of gene expression, which further
contributes to the complexity of GIST biology and variable
response to treatment (Antonescu et al, 2004).
Approximately 10–15% of GISTs that arise in adults lack
detectable mutations of KIT or PDGFRA (referred to as wild-type
GISTs). Notably, wild-type genotype is a characteristic feature of
the vast majority of GISTs, which are diagnosed in children and
adolescents and GISTs associated with familial syndromes such as
neurofibromatosis, Carney–Stratakis syndrome or the Carney
Triad (Corless et al, 2004; Miettinen and Lasota, 2006).
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www.bjcancer.comHistopathologically, GISTs are a heterogeneous group of
tumours, featuring spindle cell, epithelioid or mixed type
morphology, and showing a wide clinical spectrum from benign
to frankly malignant sarcomas (Fletcher et al, 2002; Miettinen and
Lasota, 2006). Gastrointestinal stromal tumours typically show
expression of CD117/KIT (95%) and frequently CD34 (70%)
antigens by immunostaining, yet a small fraction of GISTs lack
both diagnostic markers (Hornick and Fletcher, 2007). KIT-
negative GISTs have a predilection for the stomach and omentum
and are most commonly epithelioid or mixed cell in type. Most
KIT-negative GISTs harbour PDGFRA mutations (80%) (Heinrich
et al, 2003b; Corless et al, 2005); the others contain KIT mutations.
The diagnosis of KIT-negative GIST can be problematic. Yet, some
of the mutations detected in KIT-negative GISTs (including some
PDGFRA mutations) are known to be imatinib sensitive; therefore,
the precise diagnosis is of utmost importance and lack of
immunoreactivity for KIT in a GIST should not be used as
justification to deny patients therapy with imatinib. In this context,
mutational analysis is mandatory to confirm the diagnosis of GIST.
The most important prognostic features of GIST in regard to the
malignant potential and prognosis are tumour size (diameter of
the largest mass) and mitotic index per high-powered field
(Fletcher et al, 2002). In addition, Miettinen and Lasota (2006)
confirmed the results of earlier studies indicating that the
anatomic location affects the risk of disease recurrence, that is,
the gastric tumours showing better prognosis than small intestinal
tumours. Yet, even low risk tumours still may have a malignant
potential and the prediction of the biological behaviour of GISTs
is difficult based on pathomorphological criteria alone. Recent
studies indicate that the type of tumour mutation may be an
additional prognostic risk factor for GISTs. Thus, the deletions in
KIT exon 11, particularly those involving codons 557–558, are
associated with high metastatic risk and poor prognosis, whereas
KIT exon 11 missense mutations are correlated with longer
progression-free survival (PFS) and better overall survival (Singer
et al, 2002; Martin et al, 2005; Andersson et al, 2006; Miettinen and
Lasota, 2006; Steigen et al, 2007). In addition, duplications in the
distal part of KIT exon 11 lead to a less aggressive phenotype.
Conversely, the presence of homo-/hemizygous KIT exon 11
mutations is associated with an increased risk for metastasis and
with an adverse clinical course (Lasota et al, 2007). Gastrointest-
inal stromal tumours that are defined by a PDGFRA mutations
occur almost exclusively in the gastric location, show epithelioid
morphology and usually have a low mitotic count. In most cases,
PDGFRA-mutated GISTs are characterised by a low malignant
potential (Lasota et al, 2004, 2006). Therefore, detection of a
PDGFRA mutation in gastric GISTs may represent an additional
prognostic marker of more benign tumour behaviour.
TREATMENT – RESPONSE ACCORDING TO
MOLECULAR SUBTYPE
The KIT or PDGFRA mutations in GISTs differ in type and affect
different receptor domains (Corless et al, 2004). It is well known
that sensitivity to imatinib depends on the location of the KIT/
PDGFRA gene mutation. Imatinib effectively inhibits KIT with the
juxtamembrane-type mutation, but fails to inhibit KIT with certain
activation loop (exon 17) mutations, such as D816V in masto-
cytosis (Ma et al, 2002; Heinrich et al, 2003a,b, 2006a). Similarly,
imatinib efficiently inhibits the juxtamembrane-type PDGFRA
mutations, while some PDGFRA tyrosine kinase domain II
mutations (mainly point mutations involving codon 842, for
example, D842V) confer primary resistance to imatinib (Debiec-
Rychter et al, 2005; Heinrich et al, 2006a). The phenomenon can be
explained by the concept that some tyrosine kinase domain II-type
mutations induce stabilisation of the activation loop in an active
conformation and/or structural alteration at the imatinib-binding
site of KIT, resulting in a decreased affinity for imatinib. Moreover,
experimental in vitro studies have shown that different amino-acid
substitutions in KIT juxtamembrane domain, even at the same
codon, might also cause different structural alteration and lead
to different imatinib sensitivities (Nakagomi and Hirota, 2007).
These findings should be an important factor to consider while
determining the eligibility for adjuvant or neoadjuvant imatinib
therapies, as patients with tumours harbouring mutations
primarily resistant to imatinib will not be benefited from the
treatment. Recently, neoadjuvant approaches to downsize GISTs
prior to surgical resection and the adjuvant treatment of
intermediate- and high-risk tumours after complete or almost
complete surgical resection are evaluated in a few international
clinical trials; both approaches may possibly become routine
clinical practice in the future.
Even more importantly, data from randomised, multicenter
North American and EORTC-Australian phase II/III clinical trials
for patients with unresectable or metastatic GISTs provided clear
evidence that tumour mutational status is associated with outcome
of imatinib therapy (Heinrich et al, 2003a,b; Debiec-Rychter et al,
2006). Patients with GISTs harbouring KIT exon 11 mutations have
higher response rates and longer PFS than those whose tumours
carry KIT exon 9 mutations or with no detectable mutations.
Notably, the EORTC-Australian 62005 study demonstrated that
patients with KIT exon 9 mutations, but not those with other
tumour genotype, had significantly longer PFS when treated with
imatinib 800mgday
 1 compared with 400mgday
 1 (Debiec-
Rychter et al, 2006). The significant PFS advantage observed with
the 800mgday
 1 dose in patients with KIT exon 9 mutations in
the EORTC-Australian study was not confirmed in the North
American S0033 study. However, it remained significant
(P¼0.017) when the pooled data set was examined further in a
meta-analysis of 1640 patients who had been followed for a median
of 45 months (Van Glabbeke et al, 2007).
PREDICTIVE VALUE OF MUTATIONAL ANALYSIS
FOR IMATINIB-RESISTANT GISTs
Resistance of GIST tumours to imatinib treatment is emerging as a
clinical challenge.
Early resistance has been reported in 10–20% of cases (Demetri
et al, 2007). However, the vast majority of responding patients will
eventually develop secondary tumour progression. Development of
imatinib resistance can follow several patterns, including progres-
sion at the primary tumour site or the development of new
metastatic lesions. Available data suggest that many cases of focal
progression during imatinib therapy result from clonal evolution
(Antonescu et al, 2005; Debiec-Rychter et al, 2005; Heinrich et al,
2006a; Wardelmann et al, 2006). Depending on the series of
patients recently published, the PFS under imatinib treatment
ranges between 7 and 53 months.
Late imatinib resistance is most commonly associated with
acquisition of secondary KIT mutations in the split kinase
domains I and II (exon 13, 14 or exon 17). Some of these
mutations alter specifically the configuration of the ATP-binding
kinase pocket (V654A and T670I), inhibiting imatinib binding.
Others stabilise the active conformation of the receptor, which
also prevents imatinib binding (D820Y and N822K). Secondary
PDGFRA mutations have also been described (Debiec-Rychter
et al, 2005; Heinrich et al, 2006a). Importantly, several different
types of mutations may occur independently indicating polyclonal
resistance (Heinrich et al, 2006a; Wardelmann et al, 2006). It has
been shown that GISTs with an underlying primary KIT mutation
in exon 11, known to be the subgroup with better response rates
than other mutational subtypes, reveal more frequently secondary
mutations compared to tumours with an underlying exon 9
mutation (Antonescu et al, 2005; Debiec-Rychter et al, 2005;
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development of a secondary KIT mutation is an important escape
mechanism for tumour cells of which KIT-dependent proliferation
is chronically inhibited by imatinib.
Another putative mechanism of imatinib mesylate resistance is
KIT gene amplification (Debiec-Rychter et al, 2005). In addition, it
is proposed that other oncogenes or tumour suppressor genes may
have become important in sustaining the tumorigenic potential,
rendering the tumour independent from KIT signalling and thus,
making it insensitive to imatinib treatment (Heinrich et al, 2006a).
Identifying altered expression of genes, known to be important in
tumorigenesis, is an important research area that could lead to
validation of interesting targets for specific molecular therapies.
Since secondary resistance of GIST patients to imatinib is a
growing clinical problem, multiple novel inhibitors are in
development to interfere with kinase signalling using alternative
KIT and/or PDGFRs inhibitors or by targeting critical down-
stream-signalling proteins to regain disease control after failure of
imatinib (von Mehren, 2006).
Sunitinib mesylate (SU011248, Sutent
s, Pfizer) is approved for
imatinib-refractory GIST. Sunitinib is an oral tyrosine kinase
inhibitor that targets multiple kinases, including the vascular
endothelial growth factor receptors (VEGFR-1, VEGFR-2 and
VEGFR-3), PDGFRs, KIT, FLT3 and the receptor encoded by the
RET proto-oncogene. It has both antiangiogenic and antiproli-
ferative activities (Goodman et al, 2007). A phase III double-blind
trial comparing sunitinib with placebo was conducted in 312
patients with GIST who had documented failure or intolerance of
imatinib (Demetri et al, 2006). Only 5% of the patients who had
imatinib-resistant GIST showed objective response, but 58% had
disease stabilisation. Importantly, patients with imatinib-resistant
GISTs with KIT exon 9 mutations may benefit more from sunitinib
than those with an exon 11 mutation. In the patient group reported
by Heinrich et al (2006b), 37% of the imatinib-resistant GISTs with
a primary exon 9 mutation responded to sunitinib, as compared
with 5% of cases with a primary exon 11 mutation. PFS and overall
survival were also longer for patients with GIST with either a
primary KIT exon 9 mutation or with no detectable KIT/PDGFRA
mutation, compared with tumours with a KIT exon 11 mutation.
The confounding factor might be a higher incidence of secondary
KIT mutations in exon 11-mutant tumours, which may reflect
longer duration of imatinib therapy and therefore increase chances
for selection of mutations producing imatinib resistance in these
tumours. Sunitinib shows lower efficacy for secondary KIT
mutations in exons 17 and 18 in comparison with secondary
mutations in exons 13 and 14 (Prenen et al, 2006; Heinrich et al,
2006a,b). Given that GIST progression is a polyclonal event and a
variety of secondary, imatinib-resistant KIT mutations may be
present in parallel (Wardelmann et al, 2006), sunitinib may not be
efficient to inhibit the proliferation of the different tumour clones
present. As it will be impossible to identify all emerging resistant
tumour clones, KIT sequencing has only a limited role for
predicting clinical benefit of sunitinib, and the same holds true
for the other second-line TK inhibitors.
Nilotinib (AMN107, Novartis) is an oral tyrosine kinase
inhibitor that inhibits downstream signalling of BCR-ABL, KIT
and PDGFRs. Preclinical studies have shown better efficacy of
Nilotinib against certain KIT and PDGFRA mutations in compar-
ison with imatinib (Weisberg et al, 2006; Guo et al, 2007).
Dasatinib (BMS-354825, Bristol-Myers Squibb) is a dual SRC/
ABL inhibitor. This drug binds to the active conformation of KIT
to which imatinib cannot bind. In this perspective, dasatinib could
be a valid therapy for GIST patients expressing a secondary KIT
mutation that stabilises the receptor in its active conformation
form (Schittenhelm et al, 2006).
Sorafenib (BAY 43-9006, Nexavar
s, Bayer) is a novel biaryl urea
compound that was initially developed as a specific inhibitor of
serine–threonine kinase RAF. In addition, sorafenib inhibits
multiple receptor tyrosine kinases, including VEGFR-2, VEGFR-3,
PDGFRs and KIT. Preclinical data show that sorafenib is more
efficient, compared to nilotinib and dasatinib, to inhibit the
downstream signalling of KIT receptors containing imatinib-
resistant secondary mutations (Guo et al, 2007).
Heat-shock protein 90 inhibitors prevent heat-shock protein 90
from stabilising client proteins, like KIT. The targeted proteins are
then increasingly directed towards the proteasome for degrada-
tion. Preclinical data show that these compounds are able to
decrease downstream signalling from the receptor that contains
primary and secondary imatinib-resistant mutations by increasing
KIT degradation (Bauer et al, 2006). Clinical trials in imatinib-
resistant GIST patients are ongoing.
Additional molecular characterisation of GISTs becomes in-
creasingly important to identify which of the immense variety of
newly developed tyrosine kinase inhibitors might be successful for
the treatment of imatinib resistant GISTs. Moreover it has become
clear that identifying additional genomic alterations and establish-
ing protein and gene expression profiles in GIST might ultimately
help identify new markers of tumour behaviour, prognosis and
drug response.
MUTATIONAL ANALYSIS OF GISTs IN THE
MANAGEMENT OF THE DISEASE
The molecular characterisation of GISTs has become an essential
part of the routine management of this disease.
At first diagnosis of resectable disease, mutational analysis
mainly serves academic purposes, as the prognostic assessment
of individual cases at present is based on solid clinical and
morphological variables. However, according to recent NCCN
clinical practice guidelines, GIST mutational analysis is strongly
recommended for the primary intermediate or high-risk tumours
(Demetri et al, 2007). Additionally, in selected cases with atypical
histopathological or clinical features, molecular studies are
required to help make a clear diagnosis. Molecular techniques
are also essential to establish the diagnosis of emerging subtypes of
GIST, and to differentiate them from common GIST or other
mesenchymal malignancies.
At first diagnosis of disseminated, unresectable disease, muta-
tional analysis should be considered a standard of care, as various
studies have clearly shown that the type of mutation of GISTs
clearly correlates with key clinical outcome parameters, such as
response rate and PFS. While the results of molecular studies
might not have an immediate impact on the choice of drug or daily
dose, due to non-availability of approved treatment alternatives to
imatinib 400mg in most health care systems, patients with ‘poor
response genotype’ might be considered for more intense follow-
up, with higher frequency of early imaging assessments, including
computer tomography and/or FDG-PET. This helps in predicting
and identifying the treatment failure and to switch to a more
appropriate treatment as early as possible, and could even reduce
overall treatment costs.
In patients progressing during treatment with standard doses of
imatinib who potentially qualify for dose escalation, and in
patients failing the highest available doses of the imatinib who
are potential candidates for treatment with sunitinib, mutational
analysis of progressing lesions is of academic purposes. The
comparison between the initial genotype with the mutational
profile of refractory lesions might contribute to the further
understanding of the natural biology and evolution of GIST and
other solid tumours.
Patients failing all conventional systemic treatment options at
present qualify for clinical trials involving new targeted agents or
innovative drug combinations. In such an experimental setting, it
is absolutely crucial to gain as much information about the treated
tumour as possible, enabling the researcher to interpret the
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molecular studies are generally regarded essential. This can involve
analysis of historical tumour material, fresh biopsies of progres-
sing lesions prior to study entry or even sequential biopsies during
the conduct of the trial. The molecular profile of the tumour can be
used at study entry to enrich the patient population for better
outcome, which can help to establish the real value of a new drug
or combination. The same principle holds true for trials focusing
on preoperative (neoadjuvant) or postoperative (adjuvant or
additive) use of targeted agents in this malignancy, where
molecular studies can have major impact on trial outcome and
interpretation of the study data.
A major limitation though is the global nonavailability of cross-
validated methodology used for mutational analysis in GIST. It is
an absolute requirement to overcome this issue by sharing
biological material, co-analysing samples, comparing the results
and establish common standards between reference laboratories.
Such projects are considered within the framework of various
academic and commercial groups, but at present without visible
outcome.
In conclusion, the type of KIT or PDGFRA mutation appears to
influence tumour development and response to current therapies
and, therefore, might have profound power in assessing the
prognosis of the disease. Currently, KIT/PDGFRA mutational
analysis is mandatory for KIT-immunonegative GISTs and
strongly recommended for the primary intermediate or high-risk
tumours. With newly developed small molecule inhibitors or
alternative drug strategies, mutational analysis may become
indispensable for rationale and effective GIST treatment in the
future.
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